Cellphire, Inc.
Rockville, MD
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- JWXLUQ1AJ7M1
-
- SAM.gov registration date
- Physical address
- 9430 Key W Ave #219, Rockville, MD 20850, USA
- Website
- cellphire.com
- Founded
- 2005
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $7,775,410 |
| FY2025 | $15,814,451 |
| FY2024 | $23,172,556 |
| FY2023 | $5,032,890 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $10,364,155 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Cellphire thrombosomes | Department of Defense | $2,275,657 |
Similar vendors
About the company
Cellphire, Inc. is a biotechnology company specializing in developing next-generation platelet-derived therapeutics using their proprietary method for stabilizing blood in the dry state. They have received federal contracts and grants to provide goods and services related to blood products.
Through past prime federal contracts, Cellphire has provided research, development, and manufacturing services for lyophilized canine plasma and cryopreserved human platelets. These contracts were awarded by the Department of the Army and Defense Health Agency, set aside for total small businesses. Cellphire received over $35 million to conduct clinical trials and seek FDA approval for a cryopreserved platelet product that could provide an alternative to liquid platelets for military trauma situations.
Through past federal grants, Cellphire has conducted research on using intrinsically disordered proteins and cosolutes to induce reversible biostasis in human blood. As a subawardee, they have evaluated the suitability of an oxygen carrier for resuscitation during hemorrhagic shock, and generated thrombosomes to test as hemostatic agents alongside the oxygen carrier. The prime grantees were the University of Wyoming, University of Maryland Baltimore, and Washington University.
Quick answers
Is Cellphire, Inc. registered in SAM.gov?
Yes. Cellphire, Inc.'s SAM.gov registration is active through February 19, 2027.
What is Cellphire, Inc.'s CAGE code?
Cellphire, Inc.'s CAGE code is 48GV8, and its Unique Entity ID (UEI) is F42VPQJ8LJL4.
How much has Cellphire, Inc. received in federal contracts?
Federal contracts obligated $15,814,451 to Cellphire, Inc. in fiscal year 2025 and $51,795,306 in fiscal years 2023 through 2027.
How does Cellphire, Inc. rank among federal contractors?
Cellphire, Inc. ranked #58 in PSC AN and #95 at the Defense Health Agency in FY2025.
What is Cellphire, Inc.'s most recent federal award?
Cellphire, Inc.'s most recent federal contract award is Lyophilized canine plasma sequential phase II (W911NF20C0051), from ACC Aberdeen Proving Ground, on September 28, 2020.
On GovTribe
See Cellphire, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors